In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 951-952

  Roblin, Patricia M ^a   Hammerschlag, Margaret R ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; ERYTHROMYCIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; DRUG ACTIVITY; DRUG EFFECT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOTE; PENICILLIN RESISTANCE; PRIORITY JOURNAL;

EID: 0031976592     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.951     Document Type: Note

References (17)

1. Block, S., J. Hedrick, M. R. Hammerschlag, G. H. Cassell, and J. C. Craft. 1995. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr. Infect. Dis. J. 14:471-477.
2. Brueggemann, A. B., K. C. Kugler, and G. V. Doern. 1997. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 41:1594-1597.
3. Chirgwin, K., P. M. Roblin, and M. R. Hammerschlag. 1989. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob. Agents Chemother. 33:1634-1635.
4. Felmingham, D., M. J. Robbins, A. Leakey, H. Salman, C. Dencer, S. Clark, G. L. Ridgway, and R. N. Grüneberg. 1996. In vitro activity of BAY 12-8039 against bacterial respiratory tract pathogens, mycoplasmas and obligate anaerobic bacteria, abstr. F8, p. 101. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. Kohler, R. R. Williams, C. Kojak, and A. Rubin. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
6. Grayston, J. T., L. A. Campbell, C.-C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thom, and S. P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625.
7. Hammerschlag, M. R., C. L. Hyman, and P. M. Roblin. 1992. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:682-683.
8. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activity of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
9. Kubitza, D., H. H. Stass, W. Wingender, and J. Kuhlmann. 1996. BAY 12-8039, a new 8-methoxy-quinolone: safety (S), tolerability (T) and steady state pharmacokinetics (PK) in healthy male volunteers, abstr. F25, p. 104. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Lipsky, B. A., K. J. Tack, C.-C. Kuo, S. P. Wang, and J. T. Grayston. 1990. Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am. J. Med. 89:722-724.
11. Plouffe, J. F., M. T. Herbert, T. M. File, Jr., I. Baird, J. N. Parsons, J. B. Kahn, K. T. Rielly-Gauvin, and the Pneumonia Study Group. 1996. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob. Agents Chemother. 40:1175-1179.
12. Renaudin, H., C. M. Bebear, A. Boudjadja, and C. Bebear. 1996. In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas, abstr. F9, p. 101. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Roblin, P. M., W. Dumornay, and M. R. Hammerschlag. 1992. Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae. J. Clin. Microbiol. 30:1968-1971.
14. Roblin, P. M., G. Montalban, and M. R. Hammerschlag. 1994. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 38:1402-1403.
15. Roblin, P. M., A. Kutlin, and M. R. Hammerschlag. 1997. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 41:2033-2034.
16. Waterbury, K., J. J. Wang, M. Barbiero, J. Federici, A. C. Ohlin, and E. D. Huguenel. 1996. Efficacy of BAY 12-8039, a potent new quinolone, in mouse models of typical and atypical respiratory infection, abstr. F18, p. 103. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.